New Breast Cancer therapy approved by US FDA

The U.S. Food and Drug Administration just approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of the cancer coming back. Nerlynx is for adult patients who have been previously treated with a regimen that includes the drug trastuzumab.

HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan. Now these patients have an option to prevent this from happening.

Below are stats taken from the Canadian Cancer Society:

It is estimated that in 2017:

  • 26,300 women will be diagnosed with breast cancer. This represents 25% of all new cancer cases in women in 2017.
  • 5,000 women will die from breast cancer. This represents 13% of all cancer deaths in women in 2017.
  • On average, 72 Canadian women will be diagnosed with breast cancer every day.
  • On average, 14 Canadian women will die from breast cancer every day.
  • 230 men will be diagnosed with breast cancer and 60 will die from breast cancer.

Nerlynx is a kinase inhibitor that works by blocking several enzymes that promote cell growth.  After two years of doing the study for Nerlynx, 94.2 percent of patients treated  had not experienced cancer recurrence or death.

4 replies
  1. metal building kits
    metal building kits says:

    I am being treated for Stage 2A breast cancer
    right now — one more chemo treatment to go! My doctors have told
    me “we’re going for a cure here”, and I totally
    believe it WITHOUT QUESTION.
    Breast cancer is not automatically a death sentance you know.
    Thanks for the great article 🙂 <3<3

    • Health Vantis
      Health Vantis says:

      You are absolutely right @metalbuildingkits! Best of luck to you on your journey. We hope everything goes well and is successful!

  2. CancerEDU
    CancerEDU says:

    Hi there, thank you for the great information. I did have a question though I think you might be able to help me with.
    I was wondering, Why are antibody therapies extending the life expectation of many cancer patients but not defeating the cancer?

    It seems like it’s only delaying the inevitable… If you could
    provide a little insight I would greatly appreciate it!

    • Health Vantis
      Health Vantis says:

      Hi @CancerEDU! First and foremost, we are not physicians so we can’t answer that question from a true MD’s perspective. This answer is just my opinion: There are currently more than 100 cancers. Everyone has their own unique cells and no one cancer patient is like the other which makes treatment and therapies individual. Predicting an outcome is difficult to gage because it depends on when their cancer was found, at what stage, grade, their age, other risk factors, social history such as smoking etc. Not everyone will respond to therapies or drugs in the same way either. Therapies that have prolonged someone’s life are so crucial for research though. The longer they can keep someone alive, the better the data can be for them to study in order to find a cure. Some of the more aggressive cancers that cause people to die quickly are harder for researchers to find viable treatments because their ‘subjects’ if you will, do not live long enough for them to complete the trials and required guidelines for producing a new drug or therapy. Not only do they have to collect the data to prove it works, they also have to get it approved. Most studies and medications can take years to complete. There is also an issue for funding. They need money in order to do these studies and to create new drugs which can slow things down. I wish there was a cure for all cancers but truly believe our experts researching it do as well! Again, this is just my opinion 🙂


Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *